Status update: the Prospectus Regulation 2017
Notwithstanding the uncertainty surrounding the timing and ultimate destination of Brexit, European legislation continues to apply to capital markets in the UK.
In this regard, the Prospectus Regulation 2017 (the Regulation) is due to come fully into force from 21 July 2019 and will therefore apply to prospectuses vetted by the FCA.
Two key provisions of the Regulation came into force early, being: i) the increase in the exemption for an admission of shares of the same class as shares already admitted to the same regulated market from 10% to 20%, which has applied since July 2017; and ii) the ability to apply a total threshold below which a prospectus is not required for an offer of securities to the public, which has applied since July 2018 with the level in the UK being set at €8m. The key further provisions coming into force and which will apply to any prospectus published on or after 21 July 2019 are:
1. Prospectus summaries
The current requirement for a tabulated summary will disappear. In its place, issuers will have more discretion to decide on what information should be summarised.
Largely, the new requirements are based on Key Information Documents which certain issuers have had to produce in recent years.
There are still mandatory content requirements including: i) an introductory warning rubric; ii) key information on the issuer such as financial information and material risk factors (limited to 15 such risks); iii) key information on the securities; and iv) key information on the offer, such as use of proceeds.
The new style summary will be restricted in length to seven A4 pages and, as currently, cannot cross-reference to other parts of the prospectus.
2. Content requirements
The content requirements for a prospectus are subject to some change. The current requirement that the prospectus contains "the necessary information which is material to an investor" will remain an over-arching obligation. However, this has been extended to include the reasons for the issue and its impact on the issuer. The general circumstances of the issuer is a further factor which will need to be considered.
3. Risk Factors
Under the new regime, risk factors will need to be specific to the issuer and its securities and be material to investors in order to cut down on the number of boilerplate and generic risk factors in prospectuses. The risk factors must be set out in a number of limited categories.
The issuer may (but is not required to) classify risk factors within each such category by using a scale of low, medium and high, although issuers may be unwilling to so to avoid later problems if a risk factor previously flagged as “low” turns out to be significant.
4. Reduced disclosure regime
(a) Secondary issues
Given the Market Abuse Regulation (“MAR”) applies to listed issuers and provides an on-going disclosure regime, the Regulation brings in a reduced disclosure prospectus for secondary issues for any issuer which has been listed on a regulated market or an SME growth market for at least 18 months. In the UK, AIM and NEX Growth are classified as SME growth markets.
The mandatory information required in such a prospectus will include:
- annual and half-yearly financial information published over the 12 months prior to the date of the prospectus (which can be incorporated by reference);
- pro-forma financial information (if applicable);
- profit forecasts and estimates (if any are in the market);
- a summary of information disclosed under MAR over the 12 months prior to the prospectus;
- risk factors; and
- a working capital statement, capitalisation and indebtedness statement, a disclosure of relevant conflicts of interest, related-party transactions, and details of major shareholders.
In addition, it is further proposed that this reduced disclosure regime will also apply to an issuer seeking a move from an SME Growth Market to a regulated market where the issuer has been listed for at least two years.
(b) EU growth prospectus
The second aspect of the reduced disclosure regime is to provide streamlined content requirements for secondary issues undertaken by:
- SMEs not traded on regulated markets (SMEs being entities with a sub-€200m market cap over the previous two years or meeting certain employee, balance sheet and net turnover thresholds);
- issuers, other than SMEs, whose securities are traded on an SME growth market, with a sub-€500 million market cap over the previous three years; and
- other issuers so long as they are not traded on an MTF and with fewer than 500 employees where an offer of securities to the public in the EU does not exceed more than €20 million calculated over a period of 12 months.
5. Review by regulators
Currently, once an IPO prospectus is submitted to the FCA, they have 10 business days to review the initial draft and then aim for 5 working days to review each subsequent submission. From 21 July, the FCA will have 20 working days for the initial review but have not yet confirmed what their stated aim for subsequent submissions will be.
For “frequent issuers”, the Regulation creates a new regime whereby a “Universal Registration Document” (URD, essentially a shelf registration document) can be submitted. If an issuer has an URD approved in two consecutive years, subsequent URDs can be filed or amended without prior approval, and a prospectus using such URDs benefits from an approval process of 5 working days.
For more information, please contact Paul Arathoon.
Phase out of temporary restrictions on use of winding up petitions
Hannah takes a look at the recent UK Government announcement on statutory demands and the presentation of winding up petitions
Preparing your company for sale
We set out here some initial steps to consider in anticipation of a sale.
Overhaul of London's stock market listing regime set to significantly boost capital raising opportunities for founder led UK tech businesses
Charles Russell Speechlys advises discoverIE on its acquisition of Antenova
discoverIE is a leading international designer, manufacturer and supplier of customised electronics to industry.
Charles Russell Speechlys advises Acora on acquisition of Westgate IT
Westgate IT specialises in providing IT support to businesses in the South West.
Charles Russell Speechlys advises Grape Paradise on the acquisition of a fine wine business
Charles Russell Speechlys has advised Grape Paradise on the acquisition of the Sarment Group in the China Mainland territories.
Ongoing supply chain crisis looms large over upcoming allergen law change
The Business Magazine and The Surrey Chambers of Commerce report on the firm's involvement in the sale of Online Fuels Limited to DTN
The firm advised the shareholder management team on the sale of shares in Online Fuels to global data, analytics, and technology group, DTN.
Charles Russell Speechlys advises Appital Ltd on £2.5m Investment led by Frontline Ventures
Appital is an Equity Capital Marketplace which aims to bring innovation to Equity Capital Markets.
The Business Magazine, Insider Media, Business South and The Surrey Chambers of Commerce report on the firm's involvement in Appital's £2.5m growth capital investment
The injection will accelerate the development of Appital’s technology infrastructure, integration with financial institutions.
Healthcare team advises Country Court Care on £57m sale of three care homes
Country Court Care Group Ltd has been active almost 35 years as a nursing and care home operator.
Pei Li Kew
B[re]aking up is never easy... a lesson from the Oetker business split
Charles Russell Speechlys advises Metier on US$39m investment into Africa Mobile Networks
AMN builds, owns, operates and maintains mobile network infrastructure in Africa.
Charles Russell Speechlys advises Apposite Capital on acquisition of i2a Diagnostics
i2a is a leading provider of laboratory instruments, software and reagents for the clinical microbiology market in France.
Brace yourselves: dentists could be liable for actions of self-employed staff
Private companies and public interest – a new approach to corporate governance?
Is now the optimal time to sell your company?
Charles Russell Speechlys advises Duke Royalty on royalty financing agreement with Fairmed Healthcare AG
Duke Royalty is the leading provider of royalty finance to companies in the UK and Europe.
Charles Russell Speechlys shortlisted for Best EIS/SEIS Legal/Regulatory Adviser at 2021 EISA Awards
The Awards denote excellence and recognise the achievements of EIS/SEIS practitioners over the past year.
COVID-19 Vaccination – can an employer make it compulsory for employees?
We review what legal issues to take into account when considering to make vaccination compulsory as an employer.